# US 2013/0156856 A1 · Anticoagulant-conjugated carbon nanocapsule, antithrombotic agent containing thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156856 A1
- Document ID: US20130156856A1
- Status: Published application
- Kind: A1
- Application number: 13/669,830
- Filed: 2012-11-06
- Published: 2013-06-20
- Earliest claimed: 2011-12-19
- Assignees: Industrial Technology Research Institute
- Inventors: Patrick C.H. HSIEH; Alan C.L. TANG; Gan-Lin HWANG
- Web page: https://patentgrep.com/patent/US20130156856A1

## CPC

- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C08B 37/0075: {Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- Y10T 428/2984: Microcapsule with fluid core [includes liposome]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The embodiments provide a carbon nanocapsule conjugated with at least one of the anticoagulants on the surface and an antithrombotic drug containing the anticoagulant-conjugated carbon nanocapsule as an active ingredient. The anticoagulant-conjugated carbon nanocapsule has less cytotoxicity and good biocompatibility. A method for preparing the anticoagulant-conjugated carbon nanocapsule is also provided.

## Claims

### Claim 1

A carbon nanocapsule conjugated with at least one of anticoagulants on a surface thereof.

### Claim 2 (depends on 1)

The carbon nanocapsule as claimed in claim 1, wherein the carbon nanocapsule has a diameter of 3˜100 nm.

### Claim 3 (depends on 1)

The carbon nanocapsule as claimed in claim 1, wherein the carbon nanocapsule is hollow.

### Claim 4 (depends on 1)

The carbon nanocapsule as claimed in claim 1, wherein the carbon nanocapsule is filled with metals, metal oxides, metal carbides or alloys thereof.

### Claim 5 (depends on 4)

The carbon nanocapsule as claimed in claim 4, wherein the metal of the metals, metal oxides, metal carbides and alloys thereof is selected from a group consisting of Sc, V, Cr, Fe, Co, Ni, Y, Zr, Mo, Ru, Pd, La, Ce, Pr, Nd, Gd, Tb, Dy, Ho, Er, Tm, Lu, Ta, Os, Ir, Pt, Au, Th and U.

### Claim 6 (depends on 1)

The carbon nanocapsule as claimed in claim 1, wherein the anticoagulant comprises heparin, plasmin, serine protease, urokinase, streptokinase, warfarin, acenocoumarol, phenindione, a vitamin K antagonist, or a tissue plasminogen activator.

### Claim 7 (depends on 1)

The carbon nanocapsule as claimed in claim 1, wherein the carbon nanocapsule surface conjugates with 1˜105 anticoagulants.

### Claim 8 (depends on 1)

The carbon nanocapsule as claimed in claim 1, wherein the conjugation is via amide bond formation.

### Claim 9

An antithrombotic agent comprising a carbon nanocapsule conjugated with at least one of anticoagulants on the surface as an active ingredient.

### Claim 10 (depends on 9)

The antithrombotic agent as claimed in claim 9, wherein the carbon nanocapsule has a diameter of 3˜100 nm.

### Claim 11 (depends on 9)

The antithrombotic agent as claimed in claim 9, wherein the carbon nanocapsule is hollow.

### Claim 12 (depends on 9)

The antithrombotic agent as claimed in claim 9, wherein the carbon nanocapsule is filled with metals, metal oxides, metal carbides or alloys thereof.

### Claim 13 (depends on 12)

The antithrombotic agent as claimed in claim 12, wherein the metal of the metals, metal oxides, metal carbides and alloys thereof is selected from a group consisting of Sc, V, Cr, Fe, Co, Ni, Y, Zr, Mo, Ru, Pd, La, Ce, Pr, Nd, Gd, Tb, Dy, Ho, Er, Tm, Lu, Ta, Os, Ir, Pt, Au, Th and U.

### Claim 14 (depends on 9)

The antithrombotic agent as claimed in claim 9, wherein the anticoagulant comprises heparin, plasmin, serine protease, urokinase, streptokinase, warfarin, acenocoumarol, phenindione, a vitamin K antagonist, or a tissue plasminogen activator.

### Claim 15 (depends on 9)

The antithrombotic agent as claimed in claim 9, wherein the carbon nanocapsule surface conjugates with 1˜105 anticoagulants.

### Claim 16

A method for preparing a anticoagulant-conjugated carbon nanocapsule, comprising:
functionalizing a surface of the carbon nanocapsule;
mixing the surface-functionalized carbon nanocapsule with at least one anticoagulants; and
isolating the anticoagulant-conjugated carbon nanocapsule.

### Claim 17 (depends on 16)

The method as claimed in claim 16, wherein the carbon nanocapsule is functionalized with a carboxyl group (—COOH)

### Claim 18 (depends on 17)

The method as claimed in claim 17, wherein the carboxyl group modification is carried out by an acidic treatment.

### Claim 19 (depends on 18)

The method as claimed in claim 18, wherein the acidic treatment uses hydrochloric acid, sulfite acid or a mixture thereof.

### Claim 20 (depends on 19)

The method as claimed in claim 19, wherein the acidic treatment uses a mixed solution of hydrochloride acid and sulfate acid at equal volumes.

### Claim 21 (depends on 16)

The method as claimed in claim 16, further adding a crosslinker in the step (ii).

### Claim 22 (depends on 21)

The method as claimed in claim 21, wherein the crosslinker comprises 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide or N,N′-dicylcohexyl carbodiimide.

### Claim 23 (depends on 21)

The method as claimed in claim 21, further adding N-hydroxysulfosuccinimide in the step (ii).
